Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A clinical study of PRO 140 for the treatment of colon carcinoma patients

Trial Profile

A clinical study of PRO 140 for the treatment of colon carcinoma patients

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 30 Aug 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Leronlimab (Primary)
  • Indications Carcinoma; Colon cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 30 Aug 2018 New trial record
    • 15 Aug 2018 According to a CytoDyn media release, the company is planning to file an IND within the next few weeks to begin studies of PRO 140 for the treatment of colon carcinoma.
Restricted Access

If your organization has a subscription then there are several options available to help you access AdisInsight while working remotely. Contact us at AsktheExpert.AdisInsight@springer.com to find out more.
Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top